Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

The BRITE program and its partnerships with local universities provided Udemadu with critical hands-on training in cell culture and lab techniques. This provided a strong foundation that made his ...

The Vistria Group, LP ("Vistria"), a middle market private investment firm that seeks to deliver both superior financial returns and meaningful impact, today announced that Dr. Tony Coles, MPH will ...

NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today ...

EMD Group Holding Inc. has received a federal tax lien notice from the Internal Revenue Service indicating it owes over $33.2 ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Anthos was founded by private equity firm Blackstone's Life ... Sciences business and by Novartis in 2019 to develop, ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Oxford students each belong to a college, where they live, eat and attend small-group tutorials with teachers. Postgraduate students are more likely to live off campus and will not necessarily be ...